Guggenheim Securities maintains Buy rating on LB Pharmaceuticals, selects as Top Investment Idea
LBRX LB Pharmaceuticals Inc
$42.46 -5.03%
View chart & analysis → - 1Guggenheim Securities reaffirmed its Buy rating for LB Pharmaceuticals.
- 2Guggenheim Securities' price target of $80 represents approximately 102% upside potential compared to LB Pharmaceuticals' stock price of $39.64 as of the October 28 report.
- 3The probability of success for LB-102 as a schizophrenia treatment is projected at 75%.
So what's the key point?
Guggenheim Securities has again recommended buying LB Pharmaceuticals stock. They expect the stock to rise further, viewing the probability of success for its schizophrenia treatment at 75%.
Source Investing.com · View original ↗
Today's 5 AI picks, all freeNothing hidden: past picks and how they did against the S&P 500.